AI
| Followers | 71 |
| Posts | 3426 |
| Boards Moderated | 1 |
| Alias Born | 04/28/2004 |
Wednesday, April 10, 2013 1:20:49 PM
ONXX:
I agree. I was commenting more so from the market perception side.
I think the palbociclib data to date have been strong enough that breakthrough therapy designation is not altogether meaningful.
As a goofy aside, I think palbociclib is going to be an oft-misspelled name among investors. The allure of pablociclib is too high
Yes, but only marginally; however, many investors probably think the breakthrough therapy designation is a very big deal.
I agree. I was commenting more so from the market perception side.
I think the palbociclib data to date have been strong enough that breakthrough therapy designation is not altogether meaningful.
As a goofy aside, I think palbociclib is going to be an oft-misspelled name among investors. The allure of pablociclib is too high
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
